{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-003547","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.900844+00:00","generated_at":"2026-05-28T06:35:34.852897+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"NeuroPace Reports Preliminary 2024 Revenue Above Guidance and Appoints Scott Huennekens to Board","bullets":["Preliminary unaudited Q4 2024 revenue expected $21.0M-$21.5M (17-19% growth vs Q4 2023), full year $79.4M-$79.9M (21-22% growth), above initial guidance of $73M-$77M.","Cash and short-term investments as of Dec 31, 2024 expected $52.8M; shares outstanding 30,145,039.","Scott Huennekens appointed to Board of Directors effective Jan 6, 2025; granted options for 15,507 shares at $11.93.","NAUTILUS trial one-year follow-up on track for March 2025; data lock and analysis in Q2 2025.","Management to present at J.P. Morgan Healthcare Conference Jan 15 and host Investor Day Jan 28 in NYC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-003547","json":"https://secwatch.observer/filing/0001193125-25-003547.json","markdown":"https://secwatch.observer/filing/0001193125-25-003547.md","text":"https://secwatch.observer/filing/0001193125-25-003547.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000119312525003547/0001193125-25-003547-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000119312525003547/d889166d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-28T06:35:34.852897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d0359afa20","claim":"Scott Huennekens was appointed as Director at NeuroPace Inc.","evidence_excerpt":"appointed Scott Huennekens as a director to fill the newly created vacancy, effective as of January 6, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312525003547/0001193125-25-003547-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}